Global communications and medical education consultancy 90TEN has been shortlisted for two Pharmaceutical Market Excellence Awards (PMEAs). 90TEN’s medical education programme supporting the launch of a new treatment for moderate-to-severe plaque psoriasis will be judged in the Launch Excellence category. Meanwhile 90TEN’s PR programme to improve access to a specialist radiotherapy procedure will be judged in the Established Product Management category.
Paul Tanner, Chairman and Co-Founder at 90TEN commented: “I’m delighted that two 90TEN programmes which have the ability to significantly improve patient care have been shortlisted as finalists at PMEA. The strategic and creative approach to these programmes delivered exceptional cut-through for our clients in highly competitive environments.”
90TEN is an award-winning, global healthcare consultancy that improves the lives of people through life-changing communications and medical education. 90TEN has refined the use of behaviour change techniques in healthcare communications and education for over 15 years, and hopes to add to the 24 major industry awards it has already won for its clients at the Communiqué, PMEA, BMJ, HSJ, CIPR and PRCA Awards.
PMEA recognises and commends excellence, best practice and innovation in local, European and international markets, and rewards new, intelligent ways to improve patient care and outcomes. The 2016 PMEA event will be held in London on Wednesday, 23rd November.
